Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis
Identifieur interne : 002801 ( Main/Exploration ); précédent : 002800; suivant : 002802Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis
Auteurs : C. R. V. Tomson [Royaume-Uni] ; S. M. Channon [Royaume-Uni] ; M. K. Ward [Royaume-Uni] ; M. F. Laker [Royaume-Uni]Source :
- Nephrology Dialysis Transplantation [ 0931-0509 ] ; 1989.
Abstract
Pre-dialysis plasma oxalate concentration was measured in a cross-sectional study of 75 patients receiving maintenance haemodialysis. The aims of this study were to enable formulation of hypotheses regarding the determinants of plasma oxalate concentration and to allow preliminary examination of the possibility that hyperoxalaemia confers an increased risk of cardiac and vascular disease even in the absence of primary hyperoxaluria. Plasma oxalate concentration ranged between 7 and 76 μmol/l, mean (SD) 34.6 (18.1)μmol/l (normal range < 0.8–2.0 μmol/l). Significant correlations were found between plasma oxalate concentration and plasma creatinine, duration of dialysis, current dose of ascorbic acid, and serum phosphate, and each of these variables retained significance on multiple linear regression. Oxalate clearance across a 1 m2 hollow-fibre Cuprophan dialyser, at 500 ml/min dialysate flow and blood flow between 175 and 225 ml/min, was measured 1 h after commencement of dialysis (n=19). Mean (SD) clearance was 96.5 (27.0) ml/min. No significant association was found between self-reported maximum walking distance or the occurrence of symptons of cardiac failure and plasma oxalate concentration. No relationship was found between plasma oxalate concentration and electrocardiographic conduction disturbances (n=8) ‘major’ ST/T wave changes (n=22), ‘minor’ ST/T wave changes (n=49). Plasma oxalate was significantly greater in patients with radiologically detectable calcification of medium-sized arteries than in those without calcification, but duration of dialysis was also significantly longer in these patients. Routine haemodialysis results in marked hyperoxalaemia, which may be exacerbated by ascorbate supplementation. Oxalate clearance is similar to that of other small molecules such as creatinine and phosphate. No relationship was demonstrated between hyperoxalaemia and symptoms of cardiac disease. The question of whether hyperoxalaemia confers an increased risk of vascular calcification will only be answered definitively by prospective studies.
Url:
DOI: 10.1093/oxfordjournals.ndt.a091973
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis</title><author><name sortKey="Tomson, C R V" sort="Tomson, C R V" uniqKey="Tomson C" first="C. R. V." last="Tomson">C. R. V. Tomson</name></author><author><name sortKey="Channon, S M" sort="Channon, S M" uniqKey="Channon S" first="S. M." last="Channon">S. M. Channon</name></author><author><name sortKey="Ward, M K" sort="Ward, M K" uniqKey="Ward M" first="M. K." last="Ward">M. K. Ward</name></author><author><name sortKey="Laker, M F" sort="Laker, M F" uniqKey="Laker M" first="M. F." last="Laker">M. F. Laker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F3E70E4D3731AF750925468B9BB540CD3F7B230</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1093/oxfordjournals.ndt.a091973</idno><idno type="url">https://api.istex.fr/document/4F3E70E4D3731AF750925468B9BB540CD3F7B230/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000838</idno><idno type="wicri:Area/Main/Curation">000732</idno><idno type="wicri:Area/Main/Exploration">002801</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis</title><author><name sortKey="Tomson, C R V" sort="Tomson, C R V" uniqKey="Tomson C" first="C. R. V." last="Tomson">C. R. V. Tomson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, University of Newcastle upon Tyne, Medical School Framlington Place, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Channon, S M" sort="Channon, S M" uniqKey="Channon S" first="S. M." last="Channon">S. M. Channon</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Biochemistry, University of Newcastle upon Tyne, Medical School Framlington Place, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Ward, M K" sort="Ward, M K" uniqKey="Ward M" first="M. K." last="Ward">M. K. Ward</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, University of Newcastle upon Tyne, Medical School Framlington Place, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Laker, M F" sort="Laker, M F" uniqKey="Laker M" first="M. F." last="Laker">M. F. Laker</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Biochemistry, University of Newcastle upon Tyne, Medical School Framlington Place, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Nephrology Dialysis Transplantation</title><idno type="ISSN">0931-0509</idno><idno type="eISSN">1460-2385</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1989">1989</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="792">792</biblScope><biblScope unit="page" to="799">799</biblScope></imprint><idno type="ISSN">0931-0509</idno></series><idno type="istex">4F3E70E4D3731AF750925468B9BB540CD3F7B230</idno><idno type="DOI">10.1093/oxfordjournals.ndt.a091973</idno><idno type="ArticleID">4.9.792</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0931-0509</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Pre-dialysis plasma oxalate concentration was measured in a cross-sectional study of 75 patients receiving maintenance haemodialysis. The aims of this study were to enable formulation of hypotheses regarding the determinants of plasma oxalate concentration and to allow preliminary examination of the possibility that hyperoxalaemia confers an increased risk of cardiac and vascular disease even in the absence of primary hyperoxaluria. Plasma oxalate concentration ranged between 7 and 76 μmol/l, mean (SD) 34.6 (18.1)μmol/l (normal range < 0.8–2.0 μmol/l). Significant correlations were found between plasma oxalate concentration and plasma creatinine, duration of dialysis, current dose of ascorbic acid, and serum phosphate, and each of these variables retained significance on multiple linear regression. Oxalate clearance across a 1 m2 hollow-fibre Cuprophan dialyser, at 500 ml/min dialysate flow and blood flow between 175 and 225 ml/min, was measured 1 h after commencement of dialysis (n=19). Mean (SD) clearance was 96.5 (27.0) ml/min. No significant association was found between self-reported maximum walking distance or the occurrence of symptons of cardiac failure and plasma oxalate concentration. No relationship was found between plasma oxalate concentration and electrocardiographic conduction disturbances (n=8) ‘major’ ST/T wave changes (n=22), ‘minor’ ST/T wave changes (n=49). Plasma oxalate was significantly greater in patients with radiologically detectable calcification of medium-sized arteries than in those without calcification, but duration of dialysis was also significantly longer in these patients. Routine haemodialysis results in marked hyperoxalaemia, which may be exacerbated by ascorbate supplementation. Oxalate clearance is similar to that of other small molecules such as creatinine and phosphate. No relationship was demonstrated between hyperoxalaemia and symptoms of cardiac disease. The question of whether hyperoxalaemia confers an increased risk of vascular calcification will only be answered definitively by prospective studies.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Tomson, C R V" sort="Tomson, C R V" uniqKey="Tomson C" first="C. R. V." last="Tomson">C. R. V. Tomson</name></noRegion><name sortKey="Channon, S M" sort="Channon, S M" uniqKey="Channon S" first="S. M." last="Channon">S. M. Channon</name><name sortKey="Laker, M F" sort="Laker, M F" uniqKey="Laker M" first="M. F." last="Laker">M. F. Laker</name><name sortKey="Ward, M K" sort="Ward, M K" uniqKey="Ward M" first="M. K." last="Ward">M. K. Ward</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002801 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002801 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4F3E70E4D3731AF750925468B9BB540CD3F7B230
|texte= Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis
}}
| This area was generated with Dilib version V0.6.23. |  |